Myxedema coma in COVID-19
Open Access
- 31 July 2021
- journal article
- Published by Heighten Science Publications Corporation in Annals of Clinical Endocrinology and Metabolism
- Vol. 5 (1), 029-030
- https://doi.org/10.29328/journal.acem.1001021
Abstract
SARS-CoV-2 infection is associated with thyroid disorders. It has been reported that myxedema coma (MC) can be complicated with COVID-19. COVID-19-related thyroid disorders consist of a broad spectrum of thyroid dysfunction, from thyrotoxicosis to decompensated hypothyroidism. It is possible that both primary and central thyroid disorders are induced by COVID-19 due to systemic inflammatory and immune responses. We experienced two cases in which patients with COVID-19 developed MC with central hypothyroidism. It is likely that MC affected the severity of COVID-19. It is necessary to consider the existence of MC during SARS-CoV-2 infection. We propose the potential mechanisms.Keywords
This publication has 8 references indexed in Scilit:
- Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient managementAnnales d'Endocrinologie, 2020
- Sudden Cardiac Arrest in a Patient With Myxedema Coma and COVID-19Journal of the Endocrine Society, 2020
- Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational studyThe Lancet Respiratory Medicine, 2020
- COVID-19, hypothalamo-pituitary-adrenal axis and clinical implicationsEndocrine, 2020
- Modulating the function of the immune system by thyroid hormones and thyrotropinImmunology Letters, 2017
- Clinical characteristics and outcomes of myxedema coma: Analysis of a national inpatient database in JapanJournal of Epidemiology, 2017
- Myxedema Coma: A New Look into an Old CrisisJournal of Thyroid Research, 2011
- Pathology of the thyroid in severe acute respiratory syndromeHuman Pathology, 2006